Search results
Results from the WOW.Com Content Network
Donepezil is a centrally acting reversible acetylcholinesterase inhibitor and structurally unrelated to other anticholinesterase agents. [8] [5] Common side effects include nausea, trouble sleeping, aggression, diarrhea, feeling tired, and muscle cramps. [8] [11] Serious side effects may include abnormal heart rhythms, urinary incontinence, and ...
Donanemab can slow the progression of Alzheimer’s disease. ... The majority of side effects (82.4%) were either mild or were detected in tests but did not cause any symptoms. ... Around 50%-60% ...
Topical decongestants are decongestants applied directly to the nasal cavity. Their effectiveness by themselves in the common cold appears to have a small benefit in adults. [1] Topical decongestants should only be used by patients for a maximum of 5–7 days in a row, because rebound congestion may occur in the form of rhinitis medicamentosa ...
Donanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. [1] [2] Donanemab was developed by Eli Lilly and Company. [3] [4] The most common side effects include amyloid-related imaging abnormalities and headache. [2] Donanemab was approved for medical use in the United States in July 2024.
A new Alzheimer's drug is being hailed as a "turning point" in the fight against the disease, with researchers saying it marks the beginning of a "new era where Alzheimer's could become treatable".
Donanemab is reported to be even more effective at slowing down the progression of Alzheimer's disease and was hailed as the "best ever" treatment for the disease by scientists, the Telegraph ...
A decongestant, or nasal decongestant, is a type of pharmaceutical drug that is used to relieve nasal congestion in the upper respiratory tract. The active ingredient in most decongestants is either pseudoephedrine or phenylephrine (the latter of which has disputed effectiveness ).
The Food and Drug Administration approved a new Alzheimer’s drug from Eli Lilly that has been shown in clinical trials to modestly slow a decline in memory and thinking abilities in people with ...